HC Wainwright & Co. Reiterates Buy on Apellis Pharmaceuticals, Maintains $92 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Apellis Pharmaceuticals (NASDAQ:APLS) with a maintained price target of $92.
April 26, 2024 | 6:22 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Apellis Pharmaceuticals receives a reiterated Buy rating and a maintained $92 price target from HC Wainwright & Co.
The reiteration of a Buy rating and the maintenance of a $92 price target by a reputable analyst firm like HC Wainwright & Co. could positively influence investor sentiment towards Apellis Pharmaceuticals. This endorsement reflects confidence in the company's future performance and may lead to increased investor interest and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100